VALILTRAMIPROSATE
New Drug Approvals
OCTOBER 12, 2024
Years later, a subgroup analysis of the trial data indicated a potential positive effect in participants who carried two copies of ApoE4 ( Abushakra et al., Alzheon licensed ALZ-801 from NeuroChem and is developing it for Alzheimer’s disease. Tramiprosate was reported to inhibit Aβ42 aggregation into toxic oligomers ( Gervais et al.,
Let's personalize your content